CRI receives U.S patent for treating chronic insomnia

Consolidated Research of Richmond, Inc. (CRI) announces the awarding of United States Patent 7,654,948 - which is a novel, drug-free system for treating people suffering from the most common sleep complaint: Chronic Insomnia.

An estimated 10-20% of the industrialized world’s adult population suffers from moderate to severe chronic insomnia, yet, unlike sleep apnea, there is a significant lack of technology addressing this tremendous need. Products based on Consolidated Research's patented technologies will address this market need.